United Capital Financial Advisors LLC Invests $380.76 Million in Repligen Corporation $RGEN

United Capital Financial Advisors LLC acquired a new position in shares of Repligen Corporation (NASDAQ:RGEN) during the 2nd quarter, Holdings Channel reports. The fund acquired 2,790,650 shares of the biotechnology company’s stock, valued at approximately $380,756,000. Repligen comprises approximately 2.1% of United Capital Financial Advisors LLC’s investment portfolio, making the stock its 10th largest position.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. NewEdge Wealth LLC increased its position in Repligen by 5.3% in the fourth quarter. NewEdge Wealth LLC now owns 1,492 shares of the biotechnology company’s stock worth $244,000 after purchasing an additional 75 shares during the last quarter. UMB Bank n.a. lifted its position in Repligen by 13.8% during the fourth quarter. UMB Bank n.a. now owns 758 shares of the biotechnology company’s stock valued at $124,000 after purchasing an additional 92 shares during the last quarter. CANADA LIFE ASSURANCE Co lifted its position in Repligen by 0.3% during the third quarter. CANADA LIFE ASSURANCE Co now owns 36,599 shares of the biotechnology company’s stock valued at $4,542,000 after purchasing an additional 100 shares during the last quarter. Coldstream Capital Management Inc. grew its stake in shares of Repligen by 5.3% in the 4th quarter. Coldstream Capital Management Inc. now owns 1,992 shares of the biotechnology company’s stock worth $326,000 after buying an additional 101 shares in the last quarter. Finally, Itau Unibanco Holding S.A. grew its stake in shares of Repligen by 38.0% in the 4th quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock worth $62,000 after buying an additional 104 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Repligen Stock Up 1.0%

NASDAQ RGEN opened at $182.03 on Friday. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 52 week low of $100.99 and a 52 week high of $188.73. The firm has a market capitalization of $10.27 billion, a price-to-earnings ratio of 249.36, a PEG ratio of 3.29 and a beta of 1.03. The company has a fifty day moving average of $151.11 and a two-hundred day moving average of $132.79.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.09. The business had revenue of $204.13 million for the quarter, compared to the consensus estimate of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The business’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, analysts predict that Repligen Corporation will post 2.06 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on RGEN shares. Royal Bank Of Canada assumed coverage on shares of Repligen in a report on Thursday, May 14th. They issued an “outperform” rating and a $160.00 target price on the stock. Barclays lifted their price target on Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. JPMorgan Chase & Co. boosted their price objective on Repligen from $165.00 to $175.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Zacks Research upgraded Repligen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. Finally, Weiss Ratings upgraded Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, August 13th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $166.43.

Insider Buying and Selling

In related news, CFO Jason K. Garland sold 733 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the transaction, the chief financial officer directly owned 19,359 shares in the company, valued at approximately $2,807,055. This represents a 3.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.60% of the company’s stock.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.